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Abstract 
Background: The STAT3 transcription factor is a major intracellular signaling protein and is frequently dysregulated 
in the most common and lethal brain malignancy in adults, glioblastoma multiforme (GBM). Activation of STAT3 in 
GBM correlates with malignancy and poor prognosis. The phosphorylating signal transducer JAK2 activates STAT3 in 
response to cytokines and growth factors. Currently there are no JAK-STAT pathway inhibitors in clinical trials for GBM, 
so we sought to examine the anti-GBM activity of SAR317461 (Sanofi-Aventis), a newer generation, highly potent JAK2 
inhibitor that exhibits low toxicity and good pharmacokinetics. SAR317461 was initially approved for patient testing in 
the treatment of primary myelofibrosis (PMF), and has shown activity in preclinical models of melanoma and pulmo-
nary cancer, but has not been tested in GBM.
Methods: We hypothesized that a potent small molecule JAK2 inhibitor could overcome the heterogeneous nature 
of GBM, and suppress a range of patient derived GBM tumorsphere lines and immortalized GBM cell lines. We treated 
with SAR317461 to determine IC50 values, and using Western blot analysis we asked whether the response was linked 
to STAT3 expression. Western blot analysis, FACS, and cell viability studies were used to identify the mechanism of 
SAR317461 induced cell death.
Results: We report for the first time that the JAK2 inhibitor SAR317461 clearly inhibited STAT3 phosphorylation and 
had substantial activity against cells (IC50 1–10 µM) from 6 of 7 different patient GSC derived GBM tumorsphere lines 
and three immortalized GBM lines. One patient GSC derived line did not constitutively express STAT3 and was more 
resistant to SAR317461 (IC50 ≈25 µM). In terms of mechanism we found cleaved PARP and clear apoptosis following 
SAR317461. SAR317461 also induced autophagy and the addition of an autophagy inhibitor markedly enhanced cell 
killing by SAR317461.
Conclusions: We conclude that SAR317461 potently inhibits STAT3 phosphorylation and that it has significant activ-
ity against those GBM cells which express activated STAT3. Further studies are warranted in terms of the potential of 
SAR317461 as single and combined therapy for selectively treating human patients afflicted with GBMs expressing 
activation of the JAK2-STAT3 signaling axis.
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Background
Glioblastoma (GBM) is the most common brain cancer in 
adults and is notorious for its diffuse invasion, heterogene-
ity, treatment resistance, and dismal 5 year patient survival 
of less than 5 % [1, 2]. The current front-line GBM thera-
peutic temozolomide (TMZ) combined with intensive 
megavoltage radiotherapy exerts some benefit, but falls far 
short in terms of efficacy and systemic toxicity [3, 4]. The 
growth of human GBM cell lines and their TMZ resistance 
has been inhibited by RNA based knockdown and by small 
molecule inhibition of STAT3, a latent transcription fac-
tor that is dysregulated in many cancers [5–10]. Constitu-
tive activation of STAT3 in gliomas is positively associated 
with tumor grade [6, 7, 11], and TCGA data reveals that 
elevated STAT3 in GBM is associated with reduced patient 
survival (Fig. 1—see “Methods”).
STAT3 is a major intracellular signaling hub and its 
downstream targets include Bcl-2, Bcl-XL, c-myc, sur-
vivin, cyclin D1, vascular endothelial growth factor 
(VEGF), among others [12–15]. STAT3 is activated when 
the signal transduction protein janus kinase 2 (JAK2) is 
stimulated by any of a variety of cytokines (IL-6, IL-11) 
and growth factors (EGF, TGF-α, PDGF and HGF) to 
phosphorylate the STAT3 tyrosine 705 residue [13, 14]. 
Constitutively activated STAT3 promotes tumor cell 
cycle progression and survival, elicits angiogenesis, and 
suppresses the immune response to tumors [16]. STAT3 
is reportedly not essential to the survival of normal cells, 
but is critical to many types of cancer cells, making it a 
potentially valuable therapeutic target [16].
While positive results have been reported for JAK-
STAT inhibition in preclinical GBM models, no human 
glioma JAK-STAT inhibitor based clinical studies have 
yet been performed, although one trial for a small mol-
ecule JAK-STAT inhibitor, WP1066, is pending (U.S. 
National Clinical Trials Database—https://clinicaltrials.
gov/) [8–10]. This relative lack of activity may be a result 
of two considerations, (1) the preclinical results with 
JAK-STAT inhibition in GBM are variable, and (2) STAT3 
signaling is nuanced since STAT3 can act, paradoxically, 
as a tumor promoter or suppressor, depending on factors 
that require further clarification [17, 18]. Nonetheless we 
were encouraged by reports of selective STAT3 block-
ade using small interfering RNA (siRNA) and small hair-
pin RNAs (shRNA) and by pharmacologic agents such 
as WP1066, that have inhibited GBM cell proliferation 
in vitro and tumor growth in vivo [5, 18, 19].
Much remains to be learned about the JAK-STAT 
pathway as a potential therapeutic target in GBM, and 
recent data motivated us to pursue the hypothesis that 
a potent newer generation JAK-STAT targeted inhibi-
tor, SAR31746, could suppress multiple GBM lines rep-
resenting genetic and phenotypic heterogeneity [18]. 
Heterogeneity is a hallmark GBM characteristic that has 
stymied other agents and called into question the use 
of JAK-STAT inhibition for this disease [18]. Structure 
based design was used to develop SAR317461 (formerly 
designated as TG101209; Sanofi-Aventis, Cambridge, 
MA, USA) and its analog SAR302503, both of which are 
orally bioavailable and have well-defined pharmacokinet-
ics [20]. SAR302503 is approved for patients in primary 
myelofibrosis (PMF) and is well tolerated. SAR317461 
was designed to be highly JAK2 selective, and it has 
exhibited marked antitumor activity in several preclini-
cal models [20, 21]. To our knowledge neither compound 
has ever been tested with GBM cell lines [22, 23].
Here we report initial steps to address the following 
hypotheses; (1) that SAR317461 can overcome and kill 
immortalized, serum dependent GBM cell lines, as well 
as human GBM stem cell (GSC) derived tumorspheres 
that exhibit the genotypic and phenotypic heterogene-
ity of the human disease, (2) that the general mechanism 
of SAR317461 induced GBM cell death is apoptosis, (3) 
that sensitivity of GBM to SAR317461 depends on the 
presence of an activated JAK-STAT pathway, and (4) 
that inhibition of other survival mechanisms, specifically 
Fig. 1 TCGA data show that STAT3 expression in GBM correlates with 
lower patient survival. a Relative STAT3 expression levels according to 
GBM patient risk group based on TCGA genetic profiling. Higher risk 
individuals had higher STAT3 expression and their expression levels 
are denoted by red symbols, while lower STAT3 expression that was 
associated with lower survival (b) and lower risk is shown in green. b 
Survival curves, high risk in red indicates reduced survival; the lower 
risk group survival is denoted by green curve. P values calculated 
using log rank indicate significance at the 95 % confidence level 
(p < 0.05). Survival analysis was censored by survival months which 
means even though patients may have been lost to follow-up, partial 
data was acquired and incorporated in the survival curves according 
to study month.
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autophagy, may increase the potency of SAR317461. We 
also sought to determine whether SAR317461 affects 
the phosphorylation of STAT5 and Akt, in addition to 
STAT3, as is the case with WP1066 [24]. We present 
pilot data that for the first time chronicle the effects of 
SAR317461 on seven patient GSC derived tumorsphere 
lines and three established, immortalized GBM cell lines. 
SAR317461 exhibited potent activity against all lines that 
expressed activated STAT3, and inhibited the phospho-
rylation of STAT3 but not of STAT5 or Akt. The mecha-
nism of STAT3 induced GBM tumorsphere cell death 
was via PARP mediated apoptosis, and we further discov-
ered that autophagy inhibitors increased the anti-GBM 
effect of SAR317461. These novel data which characterize 
the activity of SAR317461 against a varied array of GBM 
lines warrant further, more comprehensive explorations 
of the JAK-STAT pathway as a target for GBM therapy.
Methods
TCGA dataset analysis
For Fig.  1 datasets were obtained from the TCGA web-
site (https://tcga-data.nci.nih.gov). The data were derived 
from 538 adult (18+ years) cases of GBM. This data-
base includes survival information and tumor samples 
acquired from patients undergo genomic profiling and 
expression analysis. Tumor samples are required to con-
tain at least 80  % tumor nuclei and no more than 50  % 
necrosis, and a secondary pathology assessment must 
confirm the samples represent GBM. For our analysis we 
used SurvExpress® which is a gene expression database 
and web-based tool (http://bioinformatica.mty.itesm.
mx/SurvExpress) based on several datasets including 
the TCGA, to provide survival analysis and risk assess-
ment using a biomarker gene list as input to a Cox pro-
portional-hazards regression [25]. Cox regression relates 
the time of death to a number of explanatory variables 
known as covariates, in this case genes. For our analysis 
STAT3 was the specific gene of interest. We analyzed 
STAT3 gene expression level with respect to GBM in 538 
subjects, and survival analysis was censored by survival 
months, which means that even though patients may 
have been lost to follow-up, partial data was incorporated 
in the survival curves. Risk analysis was performed in 
which a predicted risk for a specific patient genetic pro-
file was determined. The subjects were then partitioned 
into low risk and high risk groups [25]. STAT3 expres-
sion is shown for each risk group (Fig.  1a) and survival 
was plotted according to the Kaplan–Meier estimator 
(Fig.  1b). Cox regression and Kaplan–Meier log rank 
analysis both indicated that the survival data were signifi-
cant at the 95 % confidence level.
Reagents for cell based studies
The JAK-2 inhibitor SAR317461 was obtained from 
Targegen (now Sanofi-Aventis), Alamar Blue was pur-
chased from AbD Serotech, and Anti-pY-STAT3 and 
anti-STAT3 were purchased from Cell Signaling Inc. 
Horseradish peroxidase-linked anti-rabbit or mouse IgG 
were acquired from Jackson ImmunoResearch (West 
Grove, PA, USA), and Odyssey Inc. supplied Odyssey® 
Blocking Buffer and IRDye 680.
Establishment of primary GSC tumorspheres from GBM 
patients
GBM tissue acquisition, processing, and culture of GSCs
We have published on these methods and our tumor-
sphere lines elsewhere [26, 27]. GBM (grade IV glioma) 
tumor samples were obtained from 7 adult human 
(>21  years) surgical patients without the exclusion of 
either sex or any ethnic/racial groups, under an approved 
UCSD MCC IRB protocol (IRB #100936), with written, 
informed patient consent. IRB ethical guidelines were 
strictly followed, and patient samples were de-identi-
fied. The tumors are obtained at surgery and multiple 
samples are taken covering all parts of the tumor. The 
tumor samples were immediately washed 2–3 times with 
5–10  ml of PBS/NSC basal medium to remove blood 
and debris, and the tissue was minced for 1–3 min with 
a No. 10 scalpel blade. The minced tissue was combined 
and enzymatically dissociated by using 3–5  ml of pre-
warmed Accutase® (Life Technologies) for 10–15 min in 
a 37  °C water bath. The solution was subsequently cen-
trifuged and 10–15  ml of basal medium was added to 
the tube and filtered through a 40 micron cell strainer to 
remove clumps and debris. After further washing cells 
were plated in NSC medium supplemented with 20 ng/
ml EGF, 10 ng/ml bFGF and heparin (2 ng/ml), antibiot-
ics added, and the cultures incubated at 37 °C in 5 % CO2.
Passaging and expansion of patient GBM derived 
tumorspheres
We cultured five patient derived tumorsphere cell lines 
GBM4, GBM8, SK1035, SK987, SK892, SK429 and 
SK262. When the tumorspheres reached an average size 
of 150–200  μm in diameter, subculture was initiated. 
The content of each flask was removed and placed in an 
appropriately sized sterile tissue culture tube, and centri-
fuged at 190g for 6 min at room temperature. The super-
natant was removed and the pellet dissociated to create 
a single cell suspension. The cell suspension was centri-
fuged, the supernatant was aspirated, and the cells resus-
pended in 1 ml of NSC medium, and incubated at 37 °C 
in 5 % CO2.
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Culture of immortalized GBM lines
Human U87, U251 and A172 GBM cells were cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10 % fetal bovine serum, 4 mM glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C 
in 5 % CO2–95 % air.
Cell viability assay
The cytotoxic effect of SAR317461 was determined in 
triplicate for all 10 GBM lines using the Cell Prolifera-
tion Reagent Alamar Blue assay (AbD sciences). Cells 
(2 ×  103 cells/well, 100 µl) added to in 96-well flat-bot-
tomed plates, incubated at 37  °C and 5  % CO2–95  % 
air overnight. After exposure to the JAK2 inhibitor 
(SAR317461) at concentrations between 0.1 and 40 µM, 
for 72 h, cell viability was determined by adding Alamar 
Blue to the cells and 6–12 h later measuring fluorescence 
using excitation and emission wavelengths of 560 and 
590  nm, respectively. Results were expressed as percent 
viability  =  [F1(treated cells)  −  background/F(untreated 
cells)  −  background]  ×  100  %. Dose–response curves 
were plotted by using GraphPad® Prism software and 
EC50 values were calculated.
Western blotting
Untreated and SAR317461 treated human GBM tum-
orsphere cells were harvested by disassociation, washed 
with ice-cold PBS, and lysed in NP40 buffer contain-
ing 50 mM Tris pH 8.0, 150 mM NaCl, 0.1 % SDS, 1 % 
NP-40, 0.1  % sodium deoxycholate, protease inhibitor 
(Complete Mini®, Roche Scientific) and Phostop® (phos-
photase inhibitor, Roche Scientific). The loading control 
was GAPDH for all blots. Protein quantification was per-
formed with a BCA protein assay kit from Pierce (Fisher 
Scientific). Protein was separated by 10  % SDS-PAGE 
and transferred to nitrocellulose membranes, then trans-
ferred to nitrocellulose membranes followed by block-
ing with Odyssey® Blocking Buffer. Subsequently the 
membranes were probed with anti-STAT3, antiphospho-
STAT3, antiphospho-JAK-2, antiphospho-STAT5 and 
anti-PARP antibodies (Cell Signaling Inc.), and anti-Bcl-
XL (Santa Cruz Biotechnology) and anti-GAPDH anti-
body (Genetex). After washing with distilled water the 
membranes were incubated in blocking buffer and IRDye 
680 for 1  h under no light conditions, then scanned 
and read on an Odyssey infrared plate reader (Li-Cor 
Biosciences).
Cell cycle analysis
For cell cycle analysis, GBM4 and GBM8 glioblastoma 
cells were plated at 200,000 cells/well and incubated for 
16  h with 2  µM of SAR317461 and DMSO. Cells were 
dissociated, fixed in ice cold methanol, then incubated 
at 22  °C in for 30  min PBS containing 50ug/ml RNAse 
A. Cellular DNA was stained with 250 μl of PI (10 μg/
ml), followed by flow cytometric analysis (FACS Calibur® 
Flow Cytometer, BD Biosciences).
Autophagy analysis
For the autophagy studies the U251 cell line was engi-
neered to stably express GFP-LC3. 1 µM SAR317461 was 
added to the medium and then cell viability was meas-
ured using the MTT assay. A starvation control was 
utilized by culturing U251 cells in media without FBS. 
Also for each category, starvation control, starvation, 
and JAK2 inhibitor, a vehicle control was also used. In 
addition to the cell viability assay the cells were imaged 
on an Olympus fluorescence microscope to assess their 
morphology.
Data analysis
For the cell viability studies the overall mean average 
deviation in percent between replicates used to construct 
the IC50 curves for 10 separate cell lines was calculated 
to be approximately 8.49  %. The standard deviation of 
IC50 values for seven tumorsphere lines treated with 
SAR317461 IC50 value is approximately 8.1 with a mean 
of 4.88 (4.88  ±  8.1). Hence the IC50 of 25 for SK892, 
which does not express pSTAT3, is more than 2 standard 
deviations outside this interval. The IC50s for U87, A172 
and U251 are 7–8 μM. Statistical differences between cell 
viability obtained in cells treated with SAR317461, with 
or without autophagy inhibitors, were determined using 
a 2-tailed, paired t test and the 95 % level of confidence. 
Thus test conditions that attained p values of less than 
0.05 relative to control were declared to be statistically 
significant.
Results
TCGA data show that STAT3 expression in GBM is 
associated with lower patient survival
Analysis of TCGA data shown in Fig. 1a depicts STAT3 
gene expression according to risk group of GBM patients. 
The box graph reveals that higher expression of STAT3 
is associated with higher risk of GBM. Panel 1b of Fig. 1 
indicates that higher expression of STAT3 is associated 
with lower overall patient survival. Collectively these 
data suggest that elevated expression of STAT3, which 
is directly activated by JAK2, is associated with a weaker 
prognosis in GBM.
Expression and constitutive activation of STAT3 in glioma 
cell lines and human tumor neurosphere lines
Seven GBM-SC lines (GBM4, GBM8, SK262, SK429, 
SK1035, SK987, SK892) established from GBM 
patient-derived tumors were successfully grown as 
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neurospheres in neural stem cell medium, as shown 
by the representative images in Fig.  2a. To determine 
whether the STAT3 pathway was activated and whether 
this had any effect on response or non-response to 
SAR317461, we used immunodetection for phosphoryl-
ated STAT3 at Tyr705 in the patient derived GBM lines 
and in the immortalized A172, U87 and U251 cell lines. 
Western blot analysis with anti-phosphospecific STAT3 
(Tyr705) and anti-STAT3 showed constitutive phospho-
rylation of STAT3 in all cell lines except SK892 (Fig. 2b, 
c).
Cell viability assay
We examined the effect of the JAK2 inhibitor 
SAR317461 on cell proliferation in seven different GBM 
cell lines in  vitro. Treatment with SAR317461 with up 
to 40  µM of compound for 72  h exhibited a similar 
inhibitory effect on GBM4, GBM8, SK1035, SK987 stem 
cells and A172 cell lines with an IC50 values of 1–2 µM, 
whereas in U87 and U251 cell lines the IC50 values were 
between 5 and 8  µM. However, in the GSC derived 
SK892 tumorsphere line the inhibitory effect was com-
paratively much lower (IC50 ~25 µM) than in the other 
patient GSC derived lines, possibly because this line 
did not express pSTAT3 (Fig. 2 & Fig. 3a–e). The mean 
average deviation in percentage terms between repli-
cates for each cell viability experiment to construct the 
IC50 curves was approximately 8.49  %. The standard 
deviation of IC50 values for 7 tumorsphere lines treated 
with SAR317461 IC50 value is approximately 8.1 with 
a mean of 4.88 (4.88  ±  8.1). Hence the IC50 of 25 for 
SK892, which does not express pSTAT3, lies more than 
2 standard deviations outside this interval. The IC50s for 
U87, A172 and U251 are 7–8 μM. Taken together, these 
results suggest that SAR317461 can be used to selec-
tively target GBM cells that express activated STAT3 
(pSTAT3) (Fig. 3a–e).
Mechanism of SAR317461 induced cell death in GSC 
derived GBM tumorspheres
Down‑regulation of STAT3 phosphorylation
In order to gain mechanistic insight into how the STAT3 
pathway is inhibited by SAR317461 in GBM cells, we 
treated patient GSC derived GBM4 and GBM8 tum-
orspheres with different concentrations of inhibitor 
and performed Western Blot analysis for phosphoryl-
ated STAT3 levels. In both tumorsphere lines treatment 
with 10, 2 and 0.1 µM SAR317461 for 16 h resulted in a 
dose-dependent inhibition of phosphorylation, while 10 
and 2 µM SAR317461 rendered STAT3 phosphorylation 
Fig. 2 STAT3 phosphorylation status in GBM cell lines. a Representative images of untreated tumorspheres derived from GSCs acquired from GBM 
tumors. The images simply illustrate the rounded conformation of healthy tumorspheres. b STAT3 phosphorylation in patient derived tumorsphere 
cell lines. c Immortalized adherent cell lines.
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undetectable (Fig.  4a). STAT5 phosphorylation was not 
reduced by SAR317461.
Induction of PARP cleavage and induction of autophagy
The induction of apoptosis in GBM4 and GBM8 patient 
derived GSC tumorsphere lines by SAR317461 was evi-
denced in Western blots by cleaved poly-ADP ribose 
polymerase (PARP) in the tumorsphere cells (Fig.  4a). 
The sub-G1 population, which is comprised of apoptotic 
cells, increased after 16 h of treatment with SAR317461 
(Fig.  4b). DNA content analysis by flow cytometry 
showed increased PI staining of apoptotic cells after 
treatment with SAR317461 secondary to DNA frag-
mentation and loss of nuclear DNA content (Fig. 4b). To 
further elucidate the mechanism of SAR317461 activ-
ity we determined whether autophagy occurred after 
SAR317461 treatment and whether cell death could be 
enhanced by inhibiting autophagy, which has a protective 
role. We found that SAR317461 induced cell autophagy 
and autophagy inhibitors enhanced cell death induced by 
SAR317461 (Fig. 5a–c). 
Discussion
STAT3 is a key intracellular effector for cytokine and 
growth factor-dependent transcriptional activation 
of genes that control proliferation, differentiation and 
apoptosis of a wide range of normal as well as trans-
formed cell types [7]. Moreover, recent studies have indi-
cated that STAT3 expression in GBM is elevated (Fig. 1), 
and that GBM tumors and cell lines exhibit high levels of 
constitutively activated STAT3 relative to normal human 
astrocytes, white matter, and normal tissue surround-
ing GBM tumors [9]. However, in preclinical models 
STAT3 has been reported to play either an oncogenic or 
suppressive role depending on the genetic background 
of the tumor system, and it is this variability that has in 
part complicated the preclinical development of JAK-
STAT inhibitors [17]. For example de la Iglesia et al. [28] 
found that when EGFR is mutated STAT3 is oncogenic, 
but in tumors with PTEN mutations STAT3 can act as a 
tumor suppressor. The basis for this apparent functional 
difference is unknown. Moreover, preclinical results 
with previous JAK-STAT inhibitors produced variable 
Fig. 3 Inhibitory effect of SAR317461 on the proliferation of GBM lines. GSCs and established cells from established GBM lines were seeded into 
each well of a 96-well micro-culture plate and SAR317461 (40–0.075 μM) was added. Each point in every curve shows the mean for three samples 
and the bars are standard error of the mean. The standard deviation of IC50 values for 7 tumorsphere lines treated with SAR317461 IC50 value is 
approximately 8.1 with a mean of 4.88 (4.88 ± 8.1). Hence the IC50 of 25 for SK892, which does not express pSTAT3, lies more than 2 standard devia-
tions outside this interval. The IC50s for U87, A172 and U251 are 7-8 μM. a (SK1035, SK987 and SK892), b (GBM4 and GBM8), c (SK262, SK429) are IC50 
curves for patient derived cell lines. d IC50 curve of the U87, A172 and U251 immortalized GBM cell lines. e Shows representative images of GBM8 
cells treated with 10 µM SAR317461 and control solution (DMSO).
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levels of anti-GBM activity [22]. However the present 
study demonstrated that inhibition of STAT3 activation 
with the potent JAK2 inhibitor SAR317461 effectively 
induced apoptosis in a heterogeneous array of human 
GSC derived tumorspheres and established GBM cell 
lines. SAR317461 also triggered autophagy and impor-
tantly, the addition of an autophagy inhibitor led to 
markedly enhanced cell killing.
A major difficulty in targeting GBM is the heteroge-
neity of mutations and signaling aberrations that occur 
within a single tumor and between patient tumors [29]. 
The intra- and extratumoral heterogeneity of multiple 
GBM tumorsphere lines we tested did not appear to pre-
vent SAR317461 from exerting potent anti-tumor activ-
ity. SAR317461 suppressed cell viability in several patient 
derived GSC lines with an IC50 of 1–2  µM, as well as 
established GBM lines with an IC50 of 2–10 µM (Fig. 3). 
Notably in one patient derived line, SK892, which had no 
constitutive expression of activated STAT3 (pSTAT3) the 
IC50 was much higher (25 µM) than the other GSC lines. 
Fig. 4 SAR317461 inactivated STAT3, induced PARP cleavage to mediate apoptosis. a Western blots of phosphorylated STAT3 at Tyr705 and total 
STAT3, Bcl-Xl and Parp in GBM4 and GBM8 cells treated with different concentrations of SAR317461 and harvested at 16 h. GADPH loading control. 
b Cells were treated with the 2 µM concentrations of SAR317461 for 16 h and then subjected to flow cytometry for cell cycle analysis. i GBM4 cells 
treated with DMSO. ii GBM4 cells treated with 2 uM of SAR317461. iii GBM8 cells treated with DMSO. iv GBM8 cells treated with 2uM of SAR317461. 
Percent of cells in sub G1 phase is indicated.
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This finding is isolated but does align with the possibility 
that pSTAT3 expression may be associated with the abil-
ity of SAR317461 to exert a comparatively potent sup-
pressive effect on GBM tumors.
The present study suggests that the mechanism by 
which SAR317461 inhibits GBM tumorspheres is apop-
tosis and that PARP cleavage plays a role. The relevant 
pathways remain to be identified, although it is known 
that targets of STAT3 include various prosurvival genes 
including those for Bcl-2, Mcl-1, and Bcl-XL [17]. Fur-
thermore, it has been reported for multiple myeloma 
that SAR317461 induced down regulation of pJAK2 and 
pSTAT3 levels that correlated with up-regulation of pErk 
and pAkt, indicating cross talk between these signal-
ing pathways that is yet to be delineated in detail [22]. 
Down regulation of the antiapoptotic protein Bcl-XL has 
been reported in myeloma and U251 cells with JAK2 
inhibition, but curiously, in our patient derived GSC 
tumorspheres down-regulation of Bcl-XL was not appar-
ent in the Western blot analysis we performed [9, 30]. 
The reasons for this are unclear, although it is possible 
that SAR317461 induction of PARP cleavage and apop-
tosis in GSC tumorspheres is based on different signal-
ing than in multiple myeloma and immortalized GBM 
lines. For example Epling-Burnette et  al. [31] reported 
that induction of apoptosis was independent of Bcl-
XL regulation in large granular lymphocyte (LGL) leuke-
mia. Instead, they found reduced protein expression of 
another Bcl-2-family protein, Mcl-1 which is known to 
be modulated by STAT3 [13].
Interestingly we also found that SAR317461 induced 
autophagy in tumorspheres. Autophagy can have a cyto-
protective role in tumor cells and we found that cell 
killing was markedly enhanced by the addition of the 
autophagy inhibitor bifilomycin A, suggesting an oppor-
tunity for combined therapy. SAR317461 was designed 
to be JAK2 selective, and it would of interest to learn in 
the context of drug resistance, whether it affects the same 
targets as WP-1066, which is a JAK-STAT inhibitor that 
has shown promise and which may soon enter clinical tri-
als for GBM. WP1066 has been found to variously impact 
multiple intracellular targets, including the inhibition 
of phosphorylation of STAT3 and STAT5 and AKT, and 
activation of immune effector cells [24, 32]. SAR317461 
which was intended to be JAK2 selective, did not inhibit 
STAT5 and Akt phosphorylation, suggesting a differences 
in activity profiles between WP1066 and SAR317461 
even though both induce apoptosis [18].
SAR317461 may be useful for disseminated GBM and 
may have broader relevance beyond GBM for several 
Fig. 5 JAK2 inhibitor SAR317461 induced cell autophagy and cell autophagy inhibitors enhanced cell death induced by SAR317461. a Stable U251 
cell line expressed GFP-LC3 induced GFP clusters with 1 µM SAR317461 treatment. b Cell viability decreased dramatically after SAR317461 and cell 
autophagy inhibitors. There were three replicates per condition and for the starvation control cells were cultured in media without FBS. Statistical 
differences between cell viability obtained in cells treated with SAR317461 with or without autophagy inhibitors were determined using a 2-tailed, 
paired t test. Bars indicate standard error of the mean and p values of less than 0.05 indicated statistical significance and are denoted by asterisks 
above the columns. c Photomicrographs showing cell morphology and density with various treatments.
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reasons. STAT3 impacts stem cell maintenance in general 
as the interaction between STAT3 and other pathways 
including EGFR, Notch, Wnt, Hedgehog, Akt, mTOR, 
olig2, PKC, MAPK, NF-κB and BMP4 has been shown 
to regulate self-renewal [33]. Hence an advantage of tar-
geting STAT3 in GBM is that the inhibition of this path-
way affects multiple downstream molecules in the GSC 
tumor compartment which drives GBM and is invasive 
[34]. In terms of other central nervous system (CNS) 
diseases, it is perhaps important that STAT3 plays a role 
in astrocyte differentiation and activity, and moreover 
astrocytes are immunocompetent cells and are capable of 
secreting inflammatory mediators that may be involved 
in CNS pathology such as Alzheimer’s disease, multiple 
sclerosis, Parkinson’s disease and brain injury [35, 36]. So, 
SAR317461 could potentially be therapeutically active 
in CNS diseases involving dysfunction of astrocytes or 
astrocyte precursors.
Summary and conclusions
For this pilot study a limited number of GBM lines were 
used although all possible steps were taken to ensure that 
the data were internally consistent. Cell based studies 
utilized the same experimental methodology and analy-
sis approach. The overall mean average deviation in per-
cent between replicates used to construct the IC50 curves 
for 10 separate cell lines was calculated to be less than 
10  % (8.49  %). For Western blot analysis a loading con-
trol was used to ensure that the intensity of the visual-
ized bands was real and not an artifact of different loaded 
concentrations of the protein of interest. For studies in 
which the effect of combining autophagy inhibitors with 
SAR317461 was evaluated, we utilized both starvation 
controls and control solutions (PBS).
Our data demonstrate that SAR317461 potently inhib-
ited both STAT3 phosphorylation and induced apopto-
sis in multiple primary patient derived GSC based GBM 
tumorspheres which are genetically and phenotypi-
cally heterogeneous both internally and with respect to 
each other. SAR317461 also exhibited significant activ-
ity against three immortalized serum-dependent human 
GBM cell lines. One patient derived GBM line that did 
not express activated STAT3 showed a comparatively 
much reduced response to SAR317461, suggesting that 
pSTAT3 may need to be present for potent SAR317461 
associated anti-GBM activity, a finding that could have 
relevance from a personalized treatment perspective. 
Future explorations with a wider range of GBM lines var-
iously expressing activated STAT3 would bypass the size 
limitation of the present study and may more precisely 
define the possible dependence of SAR317461 GBM 
response on the presence of activated STAT3. Moreo-
ver, patient derived tumorsphere lines and other patient 
sourced cancer cell types resistant to standard therapy 
should be explored with SAR317461 both singly and with 
other agents and pathway inhibitors. Follow-on mecha-
nistic studies in all lines may identify a possible role of 
other Bcl-2 family proteins in the context of SAR317461 
induced apoptosis. Finally, orthotopic GBM models 
may help characterize tumor and brain concentrations 
of SAR317461 and its effects alone and in combination 
on GBM tumor proliferation, invasion, and angiogen-
esis. On the basis of the pilot results reported herein for 
SAR317461, we believe that the JAK-STAT pathway does 
merit further and comprehensive testing as a potential 
therapeutic target for GBM.
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